ALPS Medical Breakthroughs ETF (SBIO)

NYSEARCA: SBIO · IEX Real-Time Price · USD
-0.97 (-2.78%)
Aug 9, 2022 10:36 AM EDT - Market open
Assets $120.54M
NAV $34.15
Expense Ratio 0.50%
PE Ratio n/a
Shares Out 3.53M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Dec 19, 2019
1-Year Return -23.27%
Volume 3,007
Open 34.37
Previous Close 35.00
Day's Range 34.02 - 34.53
52-Week Low 23.58
52-Week High 49.64
Beta 1.04
Holdings 138
Inception Date Dec 31, 2014

About SBIO

The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Asset Class Portfolio-Multi Asset
Sector Healthcare
Region Global
Issuer ALPS Holdings
Stock Exchange NYSEARCA
Ticker Symbol SBIO
Index Tracked Poliwogg Medical Breakthroughs Index

Top 10 Holdings

25.47% of assets
Name Symbol Weight
Ionis Pharmaceuticals IONS 3.21%
CRISPR Therapeutics AG CRSP 3.20%
Intellia Therapeutics NTLA 2.58%
Arrowhead Pharmaceuticals ARWR 2.55%
Novavax NVAX 2.53%
Ascendis Pharma ASND 2.47%
Cerevel Therapeutics Holdings CERE 2.29%
Mirati Therapeutics MRTX 2.26%
Alkermes ALKS 2.23%
Denali Therapeutics DNLI 2.15%
View More Holdings


Ex-Dividend Amount Pay Date
Dec 19, 2019 $0.01585 Dec 27, 2019
Dec 20, 2018 $0.78406 Dec 27, 2018
Dec 21, 2017 $0.57949 Dec 28, 2017
Full Dividend History


Biotech & Crypto -- Best ETF Areas of Last Week

Biotech and cryptocurrency -- two ETF areas outperformed last week.

Biotech Wins Last Week: 5 Best ETFs

The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.

Other symbols: BBCBBPPFEXBI

Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal

Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Virtu...

Other symbols: BBPXBI

Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics

Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday, ...

Other symbols: BBPXBI

SBIO Increases on Biotech's Sustained Rebound

A surge in biotech stocks that began in mid-June is lasting longer than skeptics expected, with no signs of slowing down. The ALPS Medical Breakthroughs ETF (SBIO) gained 7.74% in June as positive drug ...

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Other symbols: BBCBBPCNCRXBI

Biotech ETFs Are Making a Comeback

Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech Cl...

Other symbols: BBCBBPXBI

SBIO Continues Rally on Breakthrough Drug Data

The ALPS Medical Breakthroughs ETF (SBIO) rallied 11.53% last week on positive trial data and merger and acquisition news that revived the biotech sector.  The small- and mid-cap biotech companies among...

Size Up SBIO as Biotech Catalysts Emerge

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech va...

Other symbols: BBCBBHIBB

Betting on Biotech Bear Market Expiration Date

Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader d...

Other symbols: BBCBBHIBB

Positioning for Biotech Bounceback

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that b...

Other symbols: BBCBBHIBB

Make Biotech Cash Considerations With SBIO

In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies.

Biotech Stocks, ETFs Starting to Look Healthier

Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALPS ...

Other symbols: BBCBBHIBB

SBIO Is a Good Place to Be for Biotech Innovation

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare sect...

Other symbols: BBCBBHIBB

2 Unstoppable Growth-Oriented ETFs To Hold for the Long Haul

These funds can take some of the risks out of these exciting but sometimes dangerous sectors.

Other symbols: BLOK

Small-Cap Biotech Opportunity Knocks

Among the most beaten-down assets in the first month of 2022 were biotechnology stocks, with smaller members of that group enduring significant punishment. That's the bad news.

Consolidation Could Come Calling for Biotech in 2022

Expectations are in place for a brisk pace of consolidation in the biotechnology space this year, and that could benefit an assortment of exchange traded funds, such as the ALPS Medical Breakthroughs ET...

Biotech M&A Could Finally Perk Up in 2022

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, mark...

Other symbols: BBCBBHIBB

Biotech ETFs That Outperformed Last Week

Biotech ETFs was the biggest gainer last week.

Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs

Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.

Other symbols: BBPFBTGERMPBE

Smaller Biotech Stocks Ready to Perk Up

If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more reas...

Other symbols: BBCBBHIBB

Memeification of Biotech Stocks Shines Light on This ETF

Biotechnology stocks are healthcare laggards this year, and much of the lagging is concentrated in the small- and mid-cap biotech spaces. However, retail traders are embracing some speculative small-cap...

Biotech Ready to Participate in Healthcare Bullishness

The S&P 500 Health Care Index is up almost 16% year-to-date. That's a solid showing to be sure, but biotechnology stocks and exchange traded funds are still waiting on their moments.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Sector ETF report for SBIO

September Turns Sour: Top ETF Areas of Last Week

Wall Street ended on a negative note last week just the week before that, strengthening the worth of the adage that September is historically the worst month of the year for stocks.